BCLI
HOLD / NEUTRALMeanRevComposite
56.00
Technical
84.50
Fundamental
46.50
Rank
—
Price
1.07
Hurst
0.10
As of
Sep 4, 2026
Daily
Brainstorm Cell Therapeutics Inc.
HealthcareBiotechnologyBrainstorm Cell Therapeutics is a biotechnology company developing cellular therapies derived from patients' own bone marrow stem cells to treat neurodegenerative conditions. The company's NurOwn platform uses cultured stem cells engineered to produce high levels of protective proteins that reduce inflammation and neurodegeneration while supporting nerve cell survival. The therapy is currently in clinical testing for amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, and other degenerative neurological disorders.
Market cap
$9.5M
P/E (trailing)
—
P/E (forward)
-0.84
PEG ratio
—
Dividend yield
0.00%
Beta
0.26
52w range
0.46 – 1.69
Return on equity
—
Profit margin
0.00%
Revenue growth
—
Earnings growth
—
Price history
1Y: 0.86 (+32.3%) · range 0.48–1.44
Cycle position
24/ 100 cycle scoreENTRY ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 70 · GOOD SETUP · exit proximity 0
Conviction
50/ 100 · maturity 0%
Buildup.3327
EMA entry setup.4270
Fundamentals.2547
Volume profile
POC
0.79
Price vs POC
+9.5%
Overhead supply
74%
Runway
+4.0%
Value area 0.75–1.17 · 74% of 120d volume overhead · heavy supply
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | 0.00% | +2.86% | mature |
| 40d | -21.90% | +2.86% | 34/40d |